NCT06964776

A Study of LY4268989 (MORF-057) in Healthy Participants

A Phase 1 Study to Further Investigate the Pharmacokinetics, Safety and Tolerability, Food Effect and Drug-Drug Interaction of LY4268989 (MORF-057) in Healthy Participants

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 144 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to measure the body's absorption and processing of the study drug, the study drug's effect on the body, safety, and tolerability with LY4268989 (MORF-57) in healthy participants, including Japanese and Chinese participants

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	LY4268989	Administered orally
DRUG	Placebo	Administered placebo
DRUG	Midazolam	Administered orally
DRUG	Midazolam	Administered intravenously (IV)

Timeline

• Start date: 2025-05-01
• Primary completion: 2026-02-17
• Completion: 2026-02-17
• First posted: 2025-05-09
• Last updated: 2026-03-27

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study